CRL Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 50.24%. Charles River Laboratories International's return on equity of -0.87% beat Johnson & Johnson's return on equity of 30.18%.

Charles River Laboratories International has a consensus price target of $158.94, signalling upside risk potential of 16.25%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 10.62%. Given that Charles River Laboratories International has higher upside potential than Johnson & Johnson, analysts believe Charles River Laboratories International is more attractive than Johnson & Johnson.

Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.24% to investors and pays a quarterly dividend of $1.24 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Charles River Laboratories International's net income of $25.5M is lower than Johnson & Johnson's net income of $11B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Johnson & Johnson's PE ratio is 17.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.75x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 21.68%. Charles River Laboratories International's return on equity of -0.87% beat Eli Lilly and's return on equity of 78.25%.

Charles River Laboratories International has a consensus price target of $158.94, signalling upside risk potential of 16.25%. On the other hand Eli Lilly and has an analysts' consensus of $955.31 which suggests that it could grow by 33.85%. Given that Eli Lilly and has higher upside potential than Charles River Laboratories International, analysts believe Eli Lilly and is more attractive than Charles River Laboratories International.

Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.479, suggesting its less volatile than the S&P 500 by 52.104%.

Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.79% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Charles River Laboratories International's net income of $25.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Eli Lilly and's PE ratio is 58.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.75x versus 13.15x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of 2.59% compared to Charles River Laboratories International's net margin of -907.48%. Charles River Laboratories International's return on equity of -0.87% beat Moderna's return on equity of -29.23%.

Charles River Laboratories International has a consensus price target of $158.94, signalling upside risk potential of 16.25%. On the other hand Moderna has an analysts' consensus of $47.70 which suggests that it could grow by 81.63%. Given that Moderna has higher upside potential than Charles River Laboratories International, analysts believe Moderna is more attractive than Charles River Laboratories International.

Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison Moderna has a beta of 1.995, suggesting its more volatile than the S&P 500 by 99.542%.

Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Charles River Laboratories International quarterly revenues are $984.2M, which are larger than Moderna quarterly revenues of $107M. Charles River Laboratories International's net income of $25.5M is higher than Moderna's net income of -$971M. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.75x versus 3.25x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

UnitedHealth Group has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 5.74%. Charles River Laboratories International's return on equity of -0.87% beat UnitedHealth Group's return on equity of 21.74%.

Charles River Laboratories International has a consensus price target of $158.94, signalling upside risk potential of 16.25%. On the other hand UnitedHealth Group has an analysts' consensus of $397.36 which suggests that it could grow by 34.44%. Given that UnitedHealth Group has higher upside potential than Charles River Laboratories International, analysts believe UnitedHealth Group is more attractive than Charles River Laboratories International.

Charles River Laboratories International has a beta of 1.500, which suggesting that the stock is 49.995% more volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.561, suggesting its less volatile than the S&P 500 by 43.865%.

Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.84% to investors and pays a quarterly dividend of $2.10 per share. Charles River Laboratories International pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Charles River Laboratories International's net income of $25.5M is lower than UnitedHealth Group's net income of $6.3B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while UnitedHealth Group's PE ratio is 12.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 1.75x versus 0.67x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.